Trump, Ozempic and weight loss
Digest more
Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...
The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...
Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...
Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...
The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through ...
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...
Novo Nordisk’s weaker results indicate mounting pressure in the weight-loss drug market that it once dominated. The maker of Ozempic and Wegovy is facing tougher competition, slower demand, and ...
A Novo Nordisk executive collapsed during President Trump’s announcement about lowering the cost of weight loss drugs like ...
1don MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk
Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback